Loic Perchenet
Overview
Explore the profile of Loic Perchenet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
922
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoeper M, Gomberg-Maitland M, Badesch D, Gibbs J, Grunig E, Kopec G, et al.
Eur Respir J
. 2025 Jan;
PMID: 39884760
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the...
2.
Gomberg-Maitland M, Badesch D, Gibbs J, Grunig E, Hoeper M, Humbert M, et al.
J Heart Lung Transplant
. 2024 Dec;
PMID: 39645016
Background: This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). Methods: Pooled data from PULSAR (N ...
3.
Small M, Perchenet L, Bennett A, Linder J
Ther Adv Respir Dis
. 2024 Feb;
18:17534666231218886.
PMID: 38357903
Background: Pulmonary arterial hypertension (PAH) is a life-threatening, progressive disease often diagnosed late in its course. Objectives: To present patient-reported data that were captured within a large, multinational, point-in-time survey...
4.
Distler O, Bonderman D, Coghlan J, Denton C, Grunig E, Khanna D, et al.
Arthritis Rheumatol
. 2023 Dec;
76(5):777-782.
PMID: 38146100
Objective: The evidence-based DETECT pulmonary arterial hypertension (PAH) algorithm is frequently used in patients with systemic sclerosis (SSc) to help clinicians screen for PAH by using noninvasive data to recommend...
5.
Didden E, Lee E, Wyckmans J, Quinn D, Perchenet L
Pulm Circ
. 2023 Jan;
13(1):e12188.
PMID: 36694845
The main aim of this analysis was to investigate time from symptom onset (chronic unexplained dyspnoea [CUD]) to diagnosis of Group 1 pulmonary hypertension (PH)-pulmonary arterial hypertension (PAH)-and to characterize...
6.
Chin K, Doelberg M, Martin N, Perchenet L, Galie N
J Am Coll Cardiol
. 2022 Feb;
79(7):e177.
PMID: 35177202
No abstract available.
7.
Chin K, Sitbon O, Doelberg M, Feldman J, Gibbs J, Grunig E, et al.
J Am Coll Cardiol
. 2021 Oct;
78(14):1393-1403.
PMID: 34593120
Background: In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy. Objectives: TRITON (The Efficacy and Safety of Initial Triple Versus...
8.
Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, et al.
Eur Respir J
. 2020 May;
56(3).
PMID: 32350101
No abstract available.
9.
Mouthon L, Poiraudeau S, Vernon M, Papadakis K, Perchenet L, Khanna D
Arthritis Res Ther
. 2020 Jan;
22(1):3.
PMID: 31907061
Background: We aimed to develop a patient-reported outcome measure, in accordance with the US Food and Drug Administration guidance, to capture the impact of systemic sclerosis-related digital ulcers (SSc-DUs) on...
10.
Torbicki A, Bacchi M, Delcroix M, Farber H, Ghofrani H, Hennessy B, et al.
Circ Cardiovasc Qual Outcomes
. 2019 May;
12(5):e005095.
PMID: 31109190
Background Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and logistical constraints. In many studies, such as the Study with...